Cardiometabolic Disease
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)
Scientific Publications & Presentations
Built on decades of scientific leadership, Ionis continues to advance the understanding of disease through groundbreaking research and innovation. Explore select publications across our therapeutic areas and technologies to better understand the science behind our medicines and pipeline.
Showing 37-48 out of 66 results
Other Medicines
Donidalorsen Data Presented at the American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress
Cardiometabolic Disease
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America
Neurology
ION582 Data Presented at the Angelman Syndrome Foundation Family Conference and Research Symposium
Other Medicines
Efficacy and Safety of Donidalorsen for Hereditary Angioedema
Cardiometabolic Disease
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Cardiometabolic Disease
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Cardiometabolic Disease
Olezarsen Data Presented at the 2024 American College of Cardiology Annual Meeting
Other Medicines
Data Presented at the American Society of Nephrology Kidney Week
Neurology
Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease A Randomized Clinical
Neurology
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Neurology
Eplontersen Data Presented at the American Academy of Neurology Annual Meeting